78 related articles for article (PubMed ID: 11200332)
21. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
22. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Hollas W; Blasi F; Boyd D
Cancer Res; 1991 Jul; 51(14):3690-5. PubMed ID: 1648443
[TBL] [Abstract][Full Text] [Related]
23. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system.
Vassalli JD; Wohlwend A; Belin D
Curr Top Microbiol Immunol; 1992; 181():65-86. PubMed ID: 1330446
[No Abstract] [Full Text] [Related]
24. Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit.
Dalvi N; Thomas GJ; Marshall JF; Morgan M; Bass R; Ellis V; Speight PM; Whawell SA
Biochem Biophys Res Commun; 2004 Apr; 317(1):92-9. PubMed ID: 15047152
[TBL] [Abstract][Full Text] [Related]
25. Suppression of type I collagenase expression by antisense RNA in melanoma cells results in reduced synthesis of the urokinase-type plasminogen activator receptor.
Durko M; Brodt P
Biochem Biophys Res Commun; 1998 Jun; 247(2):342-8. PubMed ID: 9642128
[TBL] [Abstract][Full Text] [Related]
26. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
Niedbala MJ; Bajetta S; Carbone R; Sartorelli AC
Cancer Commun; 1990; 2(9):317-24. PubMed ID: 2169831
[TBL] [Abstract][Full Text] [Related]
27. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
Reinartz J; Link J; Todd RF; Kramer MD
Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
[TBL] [Abstract][Full Text] [Related]
28. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis.
Ganné F; Vasse M; Beaudeux JL; Peynet J; François A; Mishal Z; Chartier A; Tobelem G; Vannier JP; Soria J; Soria C
Thromb Haemost; 2000 Oct; 84(4):680-8. PubMed ID: 11057870
[TBL] [Abstract][Full Text] [Related]
29. Immobilisation of monocytes to a solid support: a model for the study of ligand-binding interactions and plasminogen activation at the cell surface.
Soulat T; Dominguez M; Martin I; Anglés-Cano E
Thromb Res; 1999 Dec; 96(6):473-80. PubMed ID: 10632471
[TBL] [Abstract][Full Text] [Related]
30. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
31. Multiple pathways of cell invasion are regulated by multiple families of serine proteases.
Del Rosso M; Fibbi G; Pucci M; D'Alessio S; Del Rosso A; Magnelli L; Chiarugi V
Clin Exp Metastasis; 2002; 19(3):193-207. PubMed ID: 12067200
[TBL] [Abstract][Full Text] [Related]
32. Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells.
Chu EK; Cheng J; Foley JS; Mecham BH; Owen CA; Haley KJ; Mariani TJ; Kohane IS; Tschumperlin DJ; Drazen JM
Am J Respir Cell Mol Biol; 2006 Dec; 35(6):628-38. PubMed ID: 16794260
[TBL] [Abstract][Full Text] [Related]
33. Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence.
Chiaradonna F; Fontana L; Iavarone C; Carriero MV; Scholz G; Barone MV; Stoppelli MP
EMBO J; 1999 Jun; 18(11):3013-23. PubMed ID: 10357814
[TBL] [Abstract][Full Text] [Related]
34. Urokinase receptors in human monocytes.
Nykjaer A; Petersen CM; Christensen EI; Davidsen O; Gliemann J
Biochim Biophys Acta; 1990 May; 1052(3):399-407. PubMed ID: 2162216
[TBL] [Abstract][Full Text] [Related]
35. Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Lamy S; Lafleur R; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
J Cell Biochem; 2007 Jan; 100(1):100-11. PubMed ID: 16823770
[TBL] [Abstract][Full Text] [Related]
36. Modulation of receptor bound urokinase-type plasminogen activator on human monocytes by non-steroidal antiinflammatory drugs.
Kirchheimer JC
Scand J Rheumatol; 1993; 22(2):53-7. PubMed ID: 8386851
[TBL] [Abstract][Full Text] [Related]
37. [Urokinase induces adhesion of monocytes to fibrinogen].
Arefi'eva TI; Mukhina SA; Poliakov AA; Stepanova VV; Minashkin MM; Gurskiĭ IaG; Domogatskiĭ SP; Krasnikova TL
Ross Fiziol Zh Im I M Sechenova; 1998 Dec; 84(12):1432-7. PubMed ID: 10204191
[TBL] [Abstract][Full Text] [Related]
38. Urokinase binding sites on human foreskin cells. Evidence for occupancy with endogenous urokinase.
Bajpai A; Baker JB
Biochem Biophys Res Commun; 1985 Dec; 133(3):994-1000. PubMed ID: 3002380
[TBL] [Abstract][Full Text] [Related]
39. A novel urokinase receptor on monocyte-like macrophage cell line.
Bayraktutan U; Jones P
Biochem Soc Trans; 1993 Nov; 21(4):395S. PubMed ID: 8131971
[No Abstract] [Full Text] [Related]
40. A streptokinase dependent plasma factor (SKDF) induces leucocyte tissue factor activity.
Niemetz J; Kang S
Br J Haematol; 1988 Dec; 70(4):427-33. PubMed ID: 2975501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
